arrow
M

Matthew O'Sullivan

University of Sydney
H指数:34
被引数:4,612

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low influenza, pneumococcal and herpes zoster vaccination coverage in Australian patients commencing a biologic or targeted synthetic disease modifying anti-rheumatic drug for inflammatory arthritis: a nationwide cross-sectional data linkage study

澳大利亚炎症性关节炎患者在使用生物制剂或靶向合成改善病情抗风湿药物时的流感、肺炎球菌和带状疱疹疫苗接种覆盖率低:一项全国性横断面数据关联研究

2025-11-130
PRE
Convalescent plasma in hospitalised patients with COVID-19

康复期血浆在住院的COVID-19患者中

2025-11-010
PRE
Invasive Streptococcus dysgalactiae subspecies equisimilis compared with Streptococcus pyogenes in Australia, 2011–23, and the emergence of a multi-continent stG62647 lineage: a retrospective clinical and genomic epidemiology study

侵袭性 Streptococcus dysgalactiae subspecies equisimilis 与 Streptococcus pyogenes 在澳大利亚(2011–23年)的比较,以及一个多大陆 stG62647 谱系的兴起:一项回顾性临床和基因组流行病学研究

2025-10-070
OAAI
Genomic Evolution of SARS-CoV-2 Variants of Concern Under In Vitro Neutralising Selection Pressure Following Two Doses of the Pfizer-BioNTech BNT162b2 COVID-19 Vaccine

SARS-CoV-2受关注变体在体外中和选择压力下的基因组进化:继辉瑞-BioNTech BNT162b2 COVID-19疫苗两剂接种之后

2025-08-280
OA
Longer-term Mortality and Kidney Outcomes of Participants in the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial: A Post Hoc Analysis
2023-07-032
OAAI
Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine
2022-09-137
OAAI
Co-infection with SARS-CoV-2 Omicron and Delta variants revealed by genomic surveillance
2022-05-1850
OAAI
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use
2022-04-14131
OAAI
Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey

第一次流行波2020年后,澳大利亚新型冠状病毒特异性抗体的血清阳性率: 一项全国性调查

2022-01-317
OAAI
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

新型冠状病毒肺炎恢复期血浆治疗与死亡率的关系: 一项随机临床试验的协作系统评价和荟萃分析

2021-11-2050
OAAI